Skip to main content

Drug Safety

psoriatic.PIP_.JPG

Biologic Persistence in Psoriatic Arthritis and Psoriasis

May 19, 2022

Two recent studies examined the durability and persistence of biologic agents in patients with psoriasis (PSO) and psoriatic arthritis (PsA) and while some differences were noted overall persistence was low 3 years later.

Read Article
SpA,RNL,2022

RNL 2022: Spondyloarthritis Spectrum

May 18, 2022

This RheumNow Live 2022 session features highlights from lectures on Spondyloarthritis.



- Microbiome in Spondyloathritis - Jose Scher, MD



- Axial Psoriatic Arthritis - Philip Mease, MD



- Juvenile Spondyloathritis - Pamela Weiss, MD


Read Article
morbidity,covid,heart,lung,brain

Multimorbidity Burden in Rheumatoid Arthritis

May 17, 2022

Crowson and colleagues at the Mayo Clinic have shown that rheumatoid arthritis (RA) patients have a higher prevalence of multimorbidity with as many as 44 different morbidities of interest in RA.



This population-based study examined prevalent RA as of January 2015 and sought to

Read Article
lumbar,spine,lbp,pain

Acute Inflammatory Responses Needed to Resolve Chronic Pain

May 16, 2022

Science Translational Medicine has published results of a Canadian study of low back pain (LBP) suggests that pain control by anti-inflammatory treatments might have negative effects on pain duration and may be counterproductive for long-term pain outcomes.

Read Article
FDA.Safety.jpg

Bimekizumab Development Delayed by FDA

May 16, 2022

UCB announced they have received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis (PSO).

Read Article
Study of 198 RMD pts, vaccinated 91% JAKi and 80% MTX mono pts were Ab+ for spike protein. Adjusting MTX or JAKi did not significantly alter the immunogenicity (S1 spike Abs). DMARD adjustments w/ COVID-19 VAX may not be needed. https://t.co/ebw172M5I4 https://t.co/vjXqTbuD5t
Dr. John Cush @RheumNow( View Tweet )
May 16, 2022
ASCORE: Seropositivity Favors Abatacept Drug Survival The ASCORE study evaluated efficacy, safety, and drug retention (durability) of ABA in moderate-to-severe RA and found consistently better ABA durability in those who were seropositive. https://t.co/dLFC3dW4Tv https://t.co/LNCUIQjnGf
Dr. John Cush @RheumNow( View Tweet )
May 16, 2022
Can You Reduce Frequency of Methotrexate Monitoring?https://t.co/TnXZVCTv10 https://t.co/4q8sWwQ5aC
Dr. John Cush @RheumNow( View Tweet )
May 16, 2022
RheumNow Podcast square

Methotrexate Monitoring (5.13.2022)

May 13, 2022

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Bad news for digitial ulcers in Systemic sclerosis, Readmissions in Lupus and Thrombocytopenia in APL patients.




  1. Risk factors for readmission among 132,400 #SLE hospitalizatiions included

Read Article
Methotrexate

Can You Reduce Frequency of Methotrexate Monitoring?

May 12, 2022

Observational research presented at the British Society for Rheumatology meeting suggest that, based on the COVID-19 pandemic experience, reduced frequency of routine lab monitoring in patients receiving weekly methotrexate therapy for rheumatoid arthritis (RA) was not associated with an

Read Article
psoriasis,arm,hand,rash,elbow

Bimekizumab's Favorable Safety Profile in Psoriasis

May 11, 2022

A 2-year safety study of bimekizumab, the dual IL-17A/F inhibitor, plaque psoriasis patients showed bimekizumab (BMK), to be effective, well tolerated, with no new safety concerns other than a modest risk of oral candidiasis.

Read Article
PsA,Pod,RNL

RNL 2022: Psoriatic Arthritis Advances

May 11, 2022

Tuesday Nite Rheumatology on 10 May 2022 featured session highlights from RheumNow Live 2022.



This webinar presented exerpts from these lectures along with audience Q & A



  • Psoriatic Arthritis Guidelines Arthur Kavanaugh, MD

  • Drug Targeting in PsA Bruce Kirkham
Read Article
RA.Ow02.jpg

ASCORE: Seropositivity Favors Abatacept Drug Survival

May 10, 2022

The ASCORE (Abatacept SubCutaneOus in Routine clinical practicE) study evaluated efficacy, safety, and drug retention (durability) of abatacept (ABA) moderate-to-severe rheumatoid arthritis (RA) and found consistently better ABA durability in those who were seropositive. 



The study

Read Article
Evobrutinib, selective oral BTK inhibitor, has been studied in >1083 pts in phase 3 RCTs of RA, SLE, MS; shows well tolerated, most common AE ≥5% UTI (9.5%), nasopharyngitis (7.3%), diarrhea (6.2%), transient ^LFTs, SIE rate 2.72/100 PYs https://t.co/NTKYOAHhln https://t.co/oUKCDicjyA
Dr. John Cush @RheumNow( View Tweet )
May 10, 2022
Expansive (full read) review of CBD - legal and regulatory overview, availability, physiologic and pharmacologic effects, safety, & risks, standards, use in specific rheumatic disorders. https://t.co/hefwKTmPLK https://t.co/IZKZMOZ5ij
Dr. John Cush @RheumNow( View Tweet )
May 09, 2022
Three (3) Worst Drugs to use in #Lupus patients who want to be pregnant (MTX, MMF, CTX) #UTSWSLE2022 https://t.co/YBeLTuRLO1
Dr. John Cush @RheumNow( View Tweet )
May 07, 2022
RheumNow Podcast square

What is JAKne? (5.6.2022)

May 06, 2022

Dr. Jack Cush reviews the news, journal reports, FDA actions, new side effects and changing prevalence of Gout.




  1. Gout affects >10 million (4%) in USA, but now w/ more ethnicity, with highest risk in Native Hawaiians (HR 2.21), followed by Black (1.34) and Japanese (1.14);

Read Article
medical.marijuana

Lack of Research Stymies Uptake of Medical Marijuana for Rheumatic Pain

Creaky Joints
May 06, 2022

A new review article from CreakyJoints finds that there has been limited progress in understanding the potential of cannabis based therapies for the treatment of pain associated with rheumatic conditions in the past five years because of a lack of standardization of clinical research and

Read Article
acne

Acne with JAK Inhibitors

May 05, 2022

JAK inhibitors have become enormously popular and while their side effect profile has been delineated and reviewed, little mention is made of acne – an adverse event that may affect up to one-quarter of patients taking JAK inhibitors (JAKi).

Read Article
myositis.jpg

BSR Guideline on Idiopathic Inflammatory Myopathy

May 05, 2022

The British Society of Rheumatology (BSR) has published evidence-based guidelines for idiopathic inflammatory myopathy (IIM) affecting juvenile and adult-onset disease. This rare condition has an estimated prevalence of 5-15 per 100,000 persons.

Read Article
Gout pills injection

Allopurinol Use Does Not Increase Mortality in Gout with Chronic Kidney Disease

May 03, 2022

A population based trial has shown that allopurinol use dose escalation and achieving target uric acid levels (with allopurinol), was not associated with increased mortality in patients with gout and concurrent CKD



To examine the relation of allopurinol initiation, allopurinol dose

Read Article
RA, hands, MCP, deformity

Trends in Rheumatoid Arthritis Disabililty, Despite Biologics

MedPage Today
May 03, 2022

Disability claims in the U.S. related to rheumatoid arthritis (RA) were just as common in 2015 as in 1999, a government researcher found, against expectations that the advent of biologic therapy would have led to a steady decrease.



Over that 17-year period, rates of Medicare

Read Article
Patient with new onset Colitis while on secukinumab, but is this drug-induced?https://t.co/tpipGFOHI4 https://t.co/h4QujJdU8O
Dr. John Cush @RheumNow( View Tweet )
May 02, 2022
Leflunomide responses in #RA assoc w/ high metabolite levels (A77 1726). In 115 LEF Rx Pts, 40% had LDAS/remission. A77 1726 levels neg correlation w/ DAS28-ESR (r = − 0.42, p < 0.001). Levels >10µg/mL & LDAS PPV 70%; NPV 93% https://t.co/V32wUGVWLM https://t.co/L9DwZBwet9
Dr. John Cush @RheumNow( View Tweet )
May 02, 2022
FDA%20approved.jpg (keep)

Upadacitinib FDA Approved for Ankylosing Spondylitis

May 02, 2022

Abbvie has announced the US Food and Drug Administration has approved upadacitinib (Rinvoq or UPA) for use in adults with active ankylosing spondylitis, who have not responded or been intolerant of one or more TNF blockers. The recommended dose is 15 mg per day.

Read Article
×